A microRNA meta-signature for pancreatic ductal adenocarcinoma

Expert Rev Mol Diagn. 2014 Apr;14(3):267-71. doi: 10.1586/14737159.2014.893192. Epub 2014 Feb 28.

Abstract

Due to its aggressive and late presentation, there is an urgent need for novel and reliable biomarkers for the diagnosis and prognostication of pancreatic ductal adenocarcinoma (PDAC). MiRNAs have been extensively profiled in PDAC tissues, biopsies, blood samples and other biofluids and their expression levels compared to normal and chronic pancreatitis (CP) specimens in order to identify the most relevant candidates. Consolidation of these activities has not been attempted until now. The evaluated meta-review by Ma et al. helps to define the use of miRNAs as biomarkers for detecting this tumor-type and predicting survival outcomes in PDAC. Based on frequency and consistency between microarray studies, they identified a miRNA meta-signature for recognising PDAC: upregulation of miR-21, 23a, 31, 100, 143, 155, and 221; with downregulation of miR-148a, 217 and 375. Furthermore, they validated high miR-21, high miR-31 and low miR-375 tumoural expression as independently prognostic for poor overall-survival (OS; n = 70).

Publication types

  • Comment

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Carcinoma, Pancreatic Ductal / genetics*
  • Humans
  • MicroRNAs / metabolism*
  • Pancreatic Neoplasms / genetics*

Substances

  • Biomarkers, Tumor
  • MicroRNAs